Launch of Japanese version of GenomeCube®

10 May 2012

Source BioScience plc

("Source BioScience" or the "Group")

Source BioScience and DNAFORM launch Japanese version of GenomeCube®

Access to world's largest publicly available portfolio of DNA clones now available to the Japanese research community

Source BioScience (LSE: SBS), the international diagnostics and genetic analysis business of the United Kingdom, and DNAFORM, a Japanese provider of genomic products and services, announce the launch of the Japanese version of Source BioScience's GenomeCube® database and webstore.

GenomeCube® provides access to a portfolio of 20 million DNA clones and antibodies for research purposes. With the launch of the Japanese version, local research scientists will be able to access DNA clones representing nearly every known human and mouse gene, in addition to many genes from most model organisms important for biological research.

Dr Nick Ash, CEO of Source BioScience, commented: "Source BioScience has invested over £1 million in GenomeCube® to create a single, intelligent portal enabling ready access to our entire product portfolio. GenomeCube® enables us to collaborate with international franchise partners to create a global network able to access our unique portfolio. Working together with DNAFORM, our long-standing partner in Japan, we are delighted to be able to launch the first country-specific version of GenomeCube® to the Japanese life sciences research community. In the near future, we will be expanding the database to include over 7,000 research antibodies specifically targeted for the Japanese research market."

Mr Hirofumi Ujita, CEO of DNAFORM, added: "For DNAFORM, the relationship with Source Bioscience has been very important. We have worked together closely for many years providing access to genomic services to the Japanese research community, using resources from the RIKEN Omics Science Center in Japan and from Source Bioscience in the UK. We see the launch of the Japanese GenomeCube® platform as a great step forward to provide better, faster services and additional products to our customers in Japan. We are committed to further improving these offerings to become Japan's leading provider of genomic services."

--ENDS--

For further information, please contact:

Source BioScience plcNick AshChief Executive OfficerTel: +44 (0)115 973 9010www.sourcebioscience.com

For investor and media enquiries:

N+1 Brewin (Financial Advisor, Sponsor and Broker)Aubrey Powell/Luke BoyceTel: +44 (0)203 201 3710www.nplus1brewin.com

College Hill (PR Agency to Source BioScience)Melanie Toyne-Sewell/Jayne CrookTel: +44 (0)207 457 2020Mob: +44( 0)7890 022814 / +44 (0)7979 462044Email: [email protected]

K.K. DNAFORM

Hirofumi Ujita, CEOTel: +81 (0)45-510-0607Email: [email protected]

About Source BioScience:

Source BioScience plc (LSE: SBS) is an international diagnostics and genetic analysis business serving the healthcare and research markets. The LifeSciences division provides core laboratory research support from conceptualisation to implementation, calling upon a wide range of cutting-edge technology platforms including an online catalogue of biomolecular tools. The Group is a trusted provider of a complete range of sophisticated microarray, next generation and conventional sequencing services. GLP, GCP and CPA accreditations make the sequencing offerings also very attractive for applications in regulatory studies or clinical settings. Its Healthcare operations provide screening and reference laboratory diagnostic testing for cancer and other diseases and additional predictive testing for treatment optimisation for clinicians and patients. The Group has its headquarters in Nottingham, UK. Further information about Source BioScience can be found at www.sourcebioscience.com

About DNAFORM:

K.K. DNAFORM was established as the first venture company under a new initiative of the Institute of Physical and Chemical Research ('RIKEN') for the utilisation of the patented technologies developed by RIKEN scientists. With our commitment to innovative Precision Gene Technologies, developed together with the RIKEN Omics Center, we want to provide superior products and services for human diagnostics, food safety, and life science research. DNAFORM provides the research community with RIKEN FANTOM clones, established full-length cDNA cloning services, contributed to drug discovery by creating one of the world's most comprehensive human full-length cDNA collections, and developed the new Cap Analysis Gene Expression ('CAGE') methodology for next generation expression profiling in combination with genome annotation. With our innovative SMartAmp™ detection method we are now on the move to provide distinct solutions in molecular diagnostics and related applied markets. Further information about DNAFORM can be found at www.dnaform.jp